NCT05592002进行中（未招募）不适用
A Multicenter Study to Assess the Safety and Effectiveness of the Genio® Dual-sided Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnea in Subjects With Complete Concentric Collapse of the Soft Palate.
Nyxoah S.A.32 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2022年12月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 124
- 试验地点
- 32
- 主要终点
- Primary Effectiveness Endpoint
研究概览
简要总结
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
详细描述
Nyxoah has developed the Genio® 2.1 System with the intention of treating patients with moderate to severe obstructive sleep apnea.
In overview, the System includes an Implantable Stimulator (IS) designed to stimulate the hypoglossal nerve branches (i.e., both the left and the right). The IS does not include a battery but receives energy pulses transmitted by an Activation Chip (AC) which is attached to an adhesive Disposable Patch (DP) and placed on the patient's skin under the chin. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Age from 22 to 75 years (inclusive). Participant cannot be under guardianship, under curatorship or under judicial protection.
- •2. Body mass index (BMI) ≤ 32 kg/m
- •Positive cricomental space (≥ 0 cm). The cricomental space is the distance between the neck and the bisection of a line from the chin to the cricoid membrane when the head is in a neutral position.
- •4. Has either not tolerated, has failed or refused positive airway pressure (PAP) treatments.
- •5. Moderate to severe OSA (15≤AHI4≤65 where combined central and mixed AHI<25% of the total AHI) based on a screening HST and confirmed in Baseline PSG.
- •6. Complete concentric collapse at the level of the soft palate based on screening DISE.
- •7. Willing and capable of complying with all study requirements, including specific lifestyle considerations, performing all follow-up visits and sleep studies, evaluation procedures and questionnaires for the whole duration of the trial.
排除标准
- •Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment:
- •Severe chronic insomnia,
- •Insufficient sleep syndrome (<6 hours sleep per night),
- •Narcolepsy,
- •Restless legs syndrome,
- •REM behavior disorder,
- •Others deemed sufficient disorders that would confound functional sleep assessment in the judgment of the investigator.
- •Taking medications that may alter consciousness, the pattern of respiration, or sleep architecture as determined by the investigator.
- •Major anatomical or functional abnormalities that would impair the ability of the Genio® System to treat OSA:
- •Craniofacial abnormalities narrowing the airway or the implantation site,
- •Palatine tonsil size 3+ or 4+ by the Brodsky Classification,
- •Fixed upper airway obstructions (tumor, polyps, nasal obstruction),
- •Congenital malformations in the airway,
- •Hypoglossal nerve palsy (bilateral limited tongue movement, or unilateral unintended tongue deviation during protrusion),
- •Existing swallowing difficulty as measured by a score of ≥3 on the EAT-10 questionnaire
- •Others deemed sufficient to impair the ability of the Genio® System to treat OSA in the judgment of the investigator.
- •Significant comorbidities that contraindicate surgery or general anesthesia:
- •Revised Cardiac Risk Index Class III or IV,
- •Persistent uncontrolled diagnosed hypertension despite medications,
- •Coagulopathy or required anticoagulant or antiplatelet medications (such as warfarin, clopidogrel (Plavix) or similar; prophylactic aspirin not exclusionary) that cannot be safely stopped in the perioperative period, Subjects meeting any of the following criteria will be excluded from participation in this study:
- •Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment:
- •Severe chronic insomnia,
- •Insufficient sleep syndrome (<6 hours sleep per night),
- •Narcolepsy,
- •Restless legs syndrome,
- •REM behavior disorder,
- •Others deemed sufficient disorders that would confound functional sleep assessment in the judgment of the investigator.
- •Taking medications that may alter consciousness, the pattern of respiration, or sleep architecture as determined by the investigator.
- •Major anatomical or functional abnormalities that would impair the ability of the Genio® System to treat OSA:
- •Craniofacial abnormalities narrowing the airway or the implantation site,
- •Palatine tonsil size 3+ or 4+ by the Brodsky Classification,
- •Fixed upper airway obstructions (tumor, polyps, nasal obstruction),
- •Congenital malformations in the airway,
- •Hypoglossal nerve palsy (bilateral limited tongue movement, or unilateral unintended tongue deviation during protrusion),
- •Existing swallowing difficulty as measured by a score of ≥3 on the EAT-10 questionnaire
- •Others deemed sufficient to impair the ability of the Genio® System to treat OSA in the judgment of the investigator.
- •Significant comorbidities that contraindicate surgery or general anesthesia:
- •Revised Cardiac Risk Index Class III or IV,
- •Persistent uncontrolled diagnosed hypertension despite medications,
- •Coagulopathy or required anticoagulant medications (such as warfarin, clopidogrel (Plavix) or similar; prophylactic aspirin not exclusionary) that cannot be safely stopped in the perioperative period,
- •Degenerative neurological disorder (i.e., Parkinson's disease, Alzheimer's disease),
- •Acute illness or infection,
- •Any other chronic medical illness or condition that contraindicates a surgical procedure or general anesthesia in the judgment of the investigator.
- •Diagnosed psychiatric disease (e.g., psychotic illness, uncontrolled major depression or acute anxiety attacks) that prevents participant compliance with the requirements of the investigational study testing,
- •Substance or alcohol abuse history within the previous 3 years. Alcohol and substance abuse are defined as follows:
- •i. Alcohol: no days with less than 3 or 4 standard drinks for women and men respectively ii. Substance: the use of any substance in an amount unapproved by the investigator or considered illegal. The drugs most commonly abused include cocaine, marijuana, heroin (or substitution treatment), prescription drugs (especially painkillers), methamphetamines, and various other illegal substances.
- •Life expectancy of less than 12 months.
- •Prior surgery or treatments that could compromise the effectiveness of the Genio® System:
- •Airway cancer surgery or radiation,
- •Mandible or maxilla surgery in the previous 5 years (not counting dental treatments),
- 另有 5 项未显示
结局指标
主要结局
Primary Effectiveness Endpoint
时间窗: The duration of the study is expected to be approximately 4.5 years.
The effectiveness endpoint of the study is assessed through the reduction in the severity of OSA over a period of 12 months post-implant. Primary effectiveness endpoint: percentage of responders based on a change in apnea-hypopnea index (AHI4) and oxygen desaturation index (ODI4) at 12 months post-activation. A responder is defined as any subject with a reduction of 50% in AHI4 from Baseline and a remaining AHI4 \< 20 events/hour (aka "Sher Criteria"), AND 25% in ODI4 from Baseline.
次要结局
未报告次要终点
研究者
研究点 (32)
Loading locations...
相似试验
进行中（未招募）
不适用
Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)Obstructive Sleep ApneaNCT03868618Nyxoah S.A.115
尚未招募
不适用
An Extension Study to Assess the Long-term Safety of the Genio® SystemObstructive Sleep Apnea of AdultNCT05939141Nyxoah S.A.39
终止
不适用
BilatEral Hypoglossal Nerve StimulaTion for TreatmEnt of ObstRuctive SLEEP Apnoea With and Without Complete Concentric CollapseObstructive Sleep ApneaNCT03763682Nyxoah S.A.42
已完成
不适用
Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)Primary Open Angle Glaucoma (POAG)NCT02434692Implandata Ophthalmic Products GmbH24
招募中
不适用
Impact of the Cionic Neural Sleeve on Mobility in Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic ProgressiveMultiple SclerosisNCT05964829Cionic, Inc.14